ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results
October 13 2015 - 7:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that the Company will
host a conference call at 8:00 a.m. ET on Tuesday, October 27,
2015, to discuss ImmunoGen's financial results for the three-month
period ended September 30, 2015. Management also will provide an
update on the Company.
To access the live call by phone, dial 913-905-3226; the
conference ID is 9613638. The call also may be accessed through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through November 10, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member
of the Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151013005239/en/
For Investors & Media:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024